MyAlcon FitSCAN is the latest digital innovation from Alcon to transform the way you restock your trial lenses. Forget about writing down orders in a notebook or keeping an open log on the
Monoqool has introduced a new 3D technology achieving semi-transparent 3D printed glasses for the first time while also cutting back on energy used. The new Liquid 3D Technology is one of the most
In the lead-up to Silmo 2023, ‘seastainable’ pioneer Sea2see has shared a sneak preview of the brand’s new sun and optical models, offering a broad choice of shapes and designs inspired by fashion trends and a bold new style. The iconic 1970s, known for its super-sized eyewear, represents a prominen
The government’s proposal to train an additional 95 doctors each year from 2025 to 2027, on top of the 50 additional places announced for 2024, has been met with mixed responses. An additional 285
Munich-based spectacle lens and medtech company Rodenstock is expanding its presence Downunder with a new lens-glazing lab planned for Auckland early next year, a new lab in Melbourne opening in October and a further lab in Brisbane already up and running.
Eyes Right Optical’s Project Green brand is on a mission to become a world leader in environmentally friendly eyewear, said CEO Mark Wymond. Launching at O=Mega23, the new high-end brand will offer wearers who appreciate luxury eyewear an opportunity to reduce their environmental impact without comp
Viridian Therapeutics announced trial results of its intravenously delivered treatment for chronic thyroid eye disease (TED), showing patients experienced reductions in proptosis and improvements in their clinical activity scores.
A novel synthetic peptide with anti-inflammatory properties potentially suited to DED management is the subject of a phase 2 clinical trial.
Māori are a third more likely to be admitted to hospital with injuries resulting from healthcare and are 43% more likely to be admitted because of healthcare complications compared with non-Māori, reported researchers from the University of Auckland.
Inflammation plays a key role in triggering and propagating dry eye disease (DED) via the ‘vicious circle’1. In severe cases, topical anti-inflammatory therapy may be indicated, but managing a patient’s meibomian gland dysfunction can often be sufficient to resolve ocular surface inflammation withou
US researchers found mice living in a drying atmosphere had healthier and more intact corneal surfaces when given the oral probiotic Limosilactobacillus reuteri than those given saline solution alone.
Lenses marketed to filter blue light probably make no difference to digital eye strain or to sleep quality, according to a Cochrane review of 17 randomised controlled trials. Nor did the review, led